Αρχική World News Nivolumab Does Not Prolong Overall Survival Compared with Sorafenib In First-Line Treatment...

Nivolumab Does Not Prolong Overall Survival Compared with Sorafenib In First-Line Treatment for Advanced Hepatocellular Carcinoma

In CheckMate 459 study nivolumab monotherapy did not significantly prolong overall survival (OS) compared with sorafenib as first-line treatment for patients with advanced hepatocellular carcinoma. However, nivolumab showed durable clinical activity in terms of response frequency and durability, with encouraging long-term survival, a differentiated and favourable safety profile with no new safety signals. The findings are published on 13 December 2021 in The Lancet Oncology by Dr. Thomas Yau of the Department of Medicine, University of Hong Kong, Hong Kong SAR, China and colleagues.

The authors commented that since the CheckMate 459 commenced, several studies have investigated PD1 or PD-L1 inhibitors alone or in combination with other drugs as first-line therapy for advanced hepatocellular carcinoma with atezolizumab plus bevacizumab being currently the standard of care in that setting. Until 2020, the only approved first-line therapies for advanced hepatocellular carcinoma included the multikinase inhibitors sorafenib and lenvatinib.  However, treatment with these drugs results in a high proportion of treatment-related adverse events (TRAEs) which often require dose interruption or reduction.

Based on clinical activity of PD1 inhibitors in second-line treatment for advanced hepatocellular carcinoma, there is a strong rationale for their investigation in first-line setting. Single-agent nivolumab showed durable responses, manageable safety, and promising survival in patients with advanced hepatocellular carcinoma in the phase I/II CheckMate 040 study.

The confirmatory phase III CheckMate 459 study investigated nivolumab monotherapy compared with sorafenib monotherapy in patients with advanced hepatocellular carcinoma in the first-line setting. In this randomised, open-label, phase III study conducted in 22 countries, patients with no previous systemic therapy for advanced hepatocellular carcinoma with Child-Pugh class A and ECOG performance status score of 0 or 1, and regardless of viral hepatitis status were randomly assigned 1:1 to nivolumab or sorafenib until disease progression or unacceptable toxicity. The study primary endpoint was OS assessed in the intention-to-treat population. Safety was assessed in all patients who received at least one dose of study drug.

In total, 743 patients were randomly assigned, 371 to nivolumab and 372 to sorafenib. Median OS was 16.4 months (95% confidence interval [CI] 13.9–18.4) with nivolumab and 14.7 months (11.9–17.2) with sorafenib (hazard ratio 0.85, 95% CI 0.72–1.02; p = 0·075). However, the protocol-defined significance level of p = 0.0419 was not reached.

The most common grade 3 or worse TRAEs were palmar-plantar erythrodysaesthesia (<1% in the nivolumab group versus 14% patients in the sorafenib group), aspartate aminotransferase increase (6% versus 4%), and hypertension (0 versus 7%). Serious TRAEs were reported in 12% patients receiving nivolumab and 11% patients receiving sorafenib. Four deaths in the nivolumab group and one death in the sorafenib group were treatment related.

The study did not meet the prespecified boundary for significance for OS as the primary endpoint. However, improvement in response and sustained separation of the OS curves suggest a prolonged survival benefit with nivolumab at longer follow-up. Nivolumab had a manageable safety profile and no new safety signals were observed. The proportion of patients with grade 3–4 TRAEs and any-grade TRAEs leading to discontinuation was lower with nivolumab than with sorafenib.

The authors commented that based on the results from CheckMate 459, nivolumab monotherapy is included in the NCCN Clinical Practice Guidelines in the US as a first-line systemic therapy option for patients with Child-Pugh score of A or B who are ineligible for anti-angiogenic drugs or tyrosine kinase inhibitors.

The CheckMate 459 study was supported by Bristol Myers Squibb and Ono Pharmaceutical. The authors thanked Dako (an Agilent Technologies company) for collaborative development of the PD-L1 IHC 28-8 pharmDx assay.


Yau T, Park J-W, Finn RS, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. The Lancet Oncology; Published online 13 December 2021. DOI: https://doi.org/10.1016/S1470-2045(21)00604-5



Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...


Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...


ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

2-Year-Boy Is So Excited To See Himself In Disney’s ‘Encanto’

The importance of representation in media has been a growing topic of concern, and companies have responded by adding more diversity to their characters,...

Man Walks Entire Continent To Spread Awareness About Mental Health & Suicide Prevention

Matthew Fennell is walking over 3,000 miles across Australia for an important cause and one that is near and dear to his heart. Last year,...

Boy Battling Cancer Becomes Honorary Police Officer, Sworn In To 45 Agencies

At just ten years old, Devarjaye “DJ” Daniel has already been through more than most people go through in their entire lives. DJ has been...

Paclitaxel and Carboplatin Not Inferior When Compared with Paclitaxel and Ifosfamide for the Treatment of Patients with Uterine Carcinosarcoma

With regard to overall survival (OS), paclitaxel and carboplatin was not inferior and demonstrated improved progression-free survival (PFS) when compared with paclitaxel and ifosfamide...

Cancer in My Community: Improving Access to Palliative Care in Indonesia

Cancer in My Community is a Cancer.Net Blog series that shows the global impact of cancer and how people work to care for those with...

Should CAR T Cells Be Used Earlier in People with Non-Hodgkin Lymphoma?

January 13, 2022, by NCI Staff Several approved CAR T-cell therapies work by binding to the CD19 antigen on cancer cells and killing them. Credit: Adapted...